Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYHX1901 in Severe Alopecia Areata
NCT06562894Phase 2Not yet recruiting
- Sponsor
- CSPC Ouyi Pharmaceutical
- Start
- May 2025
- Primary completion
- May 2027
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of SYHX-1901 in alopecia areata (4 arms), sponsored by CSPC Ouyi Pharmaceutical. Primary endpoint: Percentage of subjects with Alopecia Severity Score Tool (SALT) score <= 20% at 24 weeks. Planned start May 2025; status: not yet recruiting.
02
Drugs
SYHX-1901
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT06562894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06562894.